At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 420 enrolled
Drug / intervention
JZP385 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel Group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor
In Brief
A Phase 2 clinical trial evaluating JZP385 and Placebo for Essential Tremor. Completed, enrolled 420 participants across 73 sites in 4 countries.
Detailed Summary
This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Tremor
CountriesGermany, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartDec 2021
Primary CompletionMay 2024
TodayJul 2026
First PostedNov 17, 2021
Enrollment StartDec 6, 2021
Primary CompletionMay 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.6 years ago
Interventions
JZP385drug
JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
Placeboother
Placebo capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.